Breakthrough Alzheimer's blood test has been approved for the US
By Bronwyn Thompson, New Atlas
May 20, 2025
The U.S. Food and Drug Administration (FDA) has approved the first-ever blood test designed to help detect Alzheimer’s disease, marking a major milestone in medical science. This new test offers a simpler and less invasive method for early diagnosis, allowing for faster intervention and improved care planning.
While a cure for Alzheimer’s remains elusive, researchers are making progress toward tools that can slow cognitive decline and improve quality of life. Earlier detection plays a critical role in making those interventions more effective.
About the New Blood Test
The test, called the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, is designed to detect early signs of amyloid plaque buildup in the brain.
Key details include:
Intended for people 55 years or older
Used when individuals show early signs of Alzheimer’s disease
Measures biomarkers associated with amyloid plaque accumulation
Provides a less invasive alternative to spinal taps and brain imaging
This advancement could make Alzheimer’s screening more accessible and reduce barriers to early diagnosis.
Learn More
Read the full article from New Atlas here:
https://newatlas.com/brain/alzheimers-dementia/breakthrough-alzheimers-blood-test/